Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GPR6 | P46095 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834429 | 1.00 | ALB (0.36) | ALBMAPK14F10RXFP1KDM1A | |
| SCHEMBL6830121 | 0.91 | ALB (0.40) | ALBRXFP1KDM1ATRPM4LMNA | |
| SCHEMBL6833872 | 0.86 | KDM1A (0.43) | ALBRXFP1KDM1ATRPM4LMNA | |
| SCHEMBL6830110 | 0.85 | PTGIR (0.39) | RXFP1MAPT | |
| SCHEMBL6835610 | 0.85 | SMN1; SMN2 (0.40) | ALBRXFP1KDM1ALMNAMAPT | |
| SCHEMBL6834267 | 0.84 | KDM1A (0.42) | ALBRXFP1KDM1ATRPM4LMNA | |
| SCHEMBL6709844 | 0.84 | MAPK14 (0.33) | MAPK14F10KDM1AJAK2NTRK1 | |
| SCHEMBL6834029 | 0.83 | KDM1A (0.42) | ALBRXFP1KDM1ATRPM4 | |
| SCHEMBL6710238 | 0.83 | MAPK14 (0.35) | MAPK14F10KDM1AJAK2NTRK1 | |
| SCHEMBL6814183 | 0.82 | MRGPRX4 (0.43) | ALBRXFP1TRPM4LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004018428-A1 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | ALB 1417/4885MAPK14 2632/4885F10 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.